coronaviru
diseas
spread
worldwid
case
itali
case
death
observ
march
world
health
associ
recent
declar
pandem
featur
infect
belong
rna
viru
famili
long
recogn
respons
infect
pet
respiratori
diseas
vari
sever
human
ie
sever
acut
respiratori
syndrom
coronaviru
abbrevi
henc
coronaviru
infect
human
divid
low
highli
pathogen
new
probabl
recombin
viru
origin
bat
recombin
take
place
within
spike
glycoprotein
recogn
cell
surfac
receptor
thu
allow
transmiss
differ
speci
virus
enter
cell
via
receptormedi
endocytosi
case
assum
angiotensin
convers
receptor
could
receptor
use
infect
lung
cell
highli
express
pulmonari
alveolar
epitheli
cell
particularli
prone
viral
infect
recent
report
china
clinic
characterist
reflect
least
three
clinic
model
patient
asymptomat
patient
mild
moder
diseas
patient
sever
pneumonia
requir
admiss
intens
care
unit
icu
common
symptom
fever
gener
elev
least
patient
dri
cough
weak
variabl
degre
dyspnoea
dyspnoea
develop
median
time
day
onset
diseas
median
time
admiss
icu
day
begin
dyspnoea
patient
requir
transfer
icu
patient
worst
evolut
show
mark
increas
plasma
cytokin
cytokin
storm
syndrom
report
provid
inform
acut
phase
reactant
includ
erythrocyt
sediment
rate
esr
creactiv
protein
crp
howev
reactant
found
high
level
cytokin
storm
patient
far
specif
antivir
treatment
avail
manag
larg
support
howev
light
grow
understand
biolog
sever
drug
commonli
use
rheumatolog
propos
potenti
treatment
chloroquin
hydroxychloroquin
hcq
antimalari
agent
immunomodul
activ
larg
use
rheumatolog
agent
also
exhibit
wellknown
antivir
activ
involv
abroad
spectrum
viral
speci
drug
work
increas
endosom
ph
inhibit
tolllik
receptor
interfer
viralcel
fusion
well
interfer
glycosyl
repres
cellular
receptor
viru
vitro
studi
demonstr
entri
postentri
antivir
activ
concentr
obtain
therapeut
dose
use
rheumatolog
furthermor
immunomodulatori
activ
agent
limit
system
immun
activ
associ
could
act
synergi
antivir
properti
numer
clinic
studi
conduct
china
patient
demonstr
superior
chloroquin
treatment
compar
placebo
inhibit
exacerb
pneumonia
improv
imag
data
promot
neg
viral
state
reduc
cours
diseas
absenc
seriou
advers
reaction
consequ
sever
regulatori
medic
agenc
chines
italian
among
includ
chloroquin
hcq
recommend
treat
recent
french
studi
patient
indic
ad
azithromycin
hcq
result
reduct
viral
load
furthermor
role
hcq
emphas
treatment
covid
infect
pregnanc
develop
cytokin
releas
syndrom
cell
abnorm
play
key
role
progress
circumst
persist
viral
stimul
lead
signific
increas
circul
cytokin
level
cytokin
neg
correl
absolut
lymphocyt
count
induc
exhaust
apoptosi
cell
trigger
inflammatori
damag
organ
play
central
role
pathogenesi
cytokin
releas
syndrom
consequ
tocilizumab
human
monoclon
antibodi
receptor
gain
interest
potenti
treatment
covid
show
treatment
tocilizumab
mgkg
improv
oxygen
satur
ct
scan
abnorm
lymphocyt
count
normal
crp
level
patient
random
clinic
trial
rct
investig
safeti
efficaci
tocilizumab
still
ongo
chines
recommend
introduc
tocilizumab
option
patient
extens
bilater
lung
diseas
serious
ill
patient
elev
level
base
chines
data
march
aifa
launch
prospect
studi
use
tocilizumab
diseas
group
patient
show
intub
respiratori
failur
first
hour
addit
studi
collect
data
patient
alreadi
treat
intub
approv
registri
tocivid
data
yet
avail
introduct
tocilizumab
patient
earlier
stage
respiratori
failur
rheumatolog
literatur
major
valu
earli
treatment
drug
progress
damag
due
inflamm
well
document
region
guidelin
introduc
dosag
cutoff
greater
pgml
criterion
therapi
tocilizumab
studi
patient
take
place
china
februari
may
roch
said
monday
march
donat
million
yuan
million
roactemra
februari
base
data
studi
start
unit
state
franc
use
anoth
receptor
monoclon
antibodi
name
sarilumab
share
sever
similar
sarscov
coronaviru
strain
respons
sar
pandem
virus
use
spike
protein
engag
cell
receptor
cell
invas
express
upregul
infect
stimul
inflammatori
cytokin
sarscov
infect
protein
induc
shed
ectodomain
process
close
coupl
product
loss
activ
caus
shed
associ
lung
injuri
consequ
increas
activ
reninangiotensin
system
although
mainli
demonstr
sarscov
homolog
protein
structur
suggest
protein
may
also
exhibit
similar
mechan
increas
product
could
consequ
facilit
viral
infect
caus
organ
damag
inde
treatment
suggest
possibl
treatment
option
rct
studi
adalimumab
recent
regist
also
also
play
pivot
role
cytokin
releas
syndrom
may
implic
interstiti
pneumonia
moreov
data
phase
rct
anakinra
inhibitor
sepsi
show
antiinflammatori
benefit
absenc
advers
event
clathrindepend
endocytosi
crucial
viral
invas
pneumocyt
process
promot
member
kinas
famili
nak
propos
limit
intracellular
viral
traffic
tyrosin
kinas
inhibitor
aim
member
nak
famili
show
good
antivir
activ
vitro
jak
inhibitor
includ
baricitinib
ruxolitinib
fedratinib
show
abil
inhibit
nak
also
limit
system
inflammatori
respons
cytokin
product
inhibit
canon
jakstat
pathway
although
baricitinib
jak
inhibitor
achiev
suffici
plasma
concentr
inhibit
nak
member
therapeut
welltoler
dose
drug
current
studi
ruxolitinib
concern
treatment
deriv
fact
earli
stage
innat
respons
virus
gener
interferon
famili
play
import
role
rapid
respons
pathogen
know
abil
jakstat
system
reduc
respons
ifn
system
form
basi
higher
herp
zoster
infect
rate
observ
therapi
howev
openlabel
pilot
studi
clinicaltrialsgov
began
march
aim
assess
percentag
patient
need
icu
current
state
show
old
new
perspect
open
antirheumat
drug
treatment
pandem
numer
italian
rheumatolog
group
struggl
make
contribut
appear
patholog
multidisciplinari
aspect
pathophysiolog
inflammatori
rheumat
diseas
review
drugrel
advers
event
help
therapeut
choic
centuri
pandem
author
declar
compet
interest
